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Abstract
Background: Coinfection with the hepatitis viruses is common in the HIV population in sub-Saharan Africa. The
aim of this study was to assess, in a cohort of HIV-infected pregnant women receiving antiretroviral drugs (ARVs),
the prevalence of HBV and HCV infections and to determine the impact of these infections on the occurrence of
liver toxicity and on the viro-immunological response.
Methods: Women were screened for HBsAg and HCV-RNA before starting, at week 25 of gestational age, an
antiretroviral regimen consisting of lamivudine and nevirapine plus either stavudine or zidovudine. Women with
CD4+ < 350/mm3 continued ARVs indefinitely, while the other women interrupted treatment 6 months postpartum
(end of breastfeeding period). Both groups were followed for 2 years after delivery. Liver function was monitored
by alanine aminotransferase (ALT) measurement. The Cox proportional hazards model was used to identify factors
associated with the emergence of liver toxicity.
Results: A total of 28 women out of the 309 enrolled in the study (9.1%) were coinfected with HBV (n. 27), or HCV
(n. 1). During follow-up 125 women (40.4%) developed a grade ≥ 1 ALT elevation, 28 (9.1%) a grade ≥ 2 and 6
(1.9%) an elevation defining grade 3 toxicity. In a multivariate model including age, baseline CD4+ count and
hemoglobin level, the presence of either HBV or HCV infection was significantly associated with the development
of an ALT increase of any grade (P = 0.035). Moderate or severe liver laboratory toxicity (grade ≥ 2) was more
frequent among women with baseline CD4+ > 250/mm3 (P = 0.030). In HBV-infected women a baseline HBV-DNA
level above 10,000 IU/ml was significantly associated to the development of liver toxicity of grade ≥ 1 (P = 0.040).
Coinfections had no impact on the immunological and virological response to antiretroviral drugs up to 2 years
after delivery.
Conclusions: In this cohort of nevirapine-treated women the presence of HBV or HCV was associated only to the
development of mild liver toxicity, while the occurrence of moderate or severe hepatoxicity was correlated to a
baseline CD4+ count > 250/mm3. No statistically significant effect of the coinfections was observed on the efficacy
of antiretroviral therapy.
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Background
Coinfection with the hepatitis B (HBV) or C (HCV) vi-
ruses occurs frequently in the HIV-infected population.
Prevalence of the coinfections differs depending on the
geographical areas: HCV is more prevalent in western
countries, while HBV is highly endemic in sub-Saharan
Africa and Asia [1]. The impact of these coinfections
in the HIV-population in resource-limited countries
has not been fully elucidated, although some studies
have reported an increase in liver toxicity in the coin-
fected patients [2-4], and others have shown little in-
fluence on the response to antiretroviral treatment
[5,6]. Limited information is available on the possible
interactions between the presence of hepatitis coinfec-
tions and the administration of potentially hepatotoxic
drugs including the non-nucleoside reverse transcriptase
inhibitor, nevirapine [7]. Data obtained on this topic
during pregnancy are particularly relevant, because of
the increased risk of drug-related toxicity reported for
HIV-infected pregnant women [8].
The aim of this study was to evaluate the role of the
coinfection with hepatitis B or C viruses on the develop-
ment of liver toxicity and on the virological and immuno-
logical response in HIV-infected pregnant women receiving
a nevirapine-based antiretroviral combination regimen,
either for prevention of mother-to-infant transmission
only, or for treatment of their own health.
Methods
Study population
Patient population included women enrolled in the SMAC
(Safe Milk for African Children) study, an observational
study conducted in Malawi and aimed to assess the safety
and pharmacokinetics of ART (Anti Retroviral Therapy)
administration to breastfeeding women [9]. The study
was conducted within the DREAM (Drug Resources
Enhancement against AIDS and Malnutrition) Program,
designed and managed by the Community of S. Egidio,
an italian faith-based non-governmental organization. The
study was approved by the National Health Sciences
Research Committee of Malawi (approval number #486).
A separate informed consent was signed by all participants.
HIV-positive pregnant women, naive to antiretrovirals,
older than 16, with no baseline grade 3 or 4 laboratory
toxicity and no concomitant treatment for tuberculosis
were eligible for the study. ART was administered as
soon as possible after the first trimester if the women
met the criteria for treatment (CD4+ < 350/mm3), and
treatment was continued indefinitely after pregnancy. The
women not needing treatment for themselves received
antiretroviral prophylaxis from week 25 of gestational
age until 6 months after delivery, which represented the
recommended duration of breastfeeding at the time of
the study (enrolment occurred between February 2008
and February 2009). All women received a combination
regimen based on lamivudine (3TC, 150 mg twice daily)
and nevirapine (NVP, 200 mg twice daily) plus either
stavudine (d4T, 30 mg twice daily) or zidovudine (ZDV,
300 mg twice daily). Women experiencing nevirapine-
associated toxicity were allowed to substitute this drug
with lopinavir-ritonavir (LPV/r, 400/100 twice daily).
Women were followed for 2 years after delivery. Complete
blood count (Sysmex KX-21N hematology analyzer, Sysmex
Corporation, Kobe, Japan) and liver enzymes (Humastar
180 Chemistry Analyzer, Human Diagnostics, Germany)
were determined every 2 weeks for the first 2 months
and every month thereafter during pregnancy, at 1, 3 and
6 months postpartum and then every three months until
24 months. CD4+ cell count (Epics XL-MCL, Beckman
Coulter, Brea, CA, USA) and HIV-RNA determination
(branched-DNA version 3.0 assay, Siemens Diagnostics,
Deerfield, IL, USA) were performed every 6 months after
delivery. Laboratory abnormalities were classified according
to the Division of Acquired Immunodeficiency Syndrome/
National Institute of Allergy and Infectious Diseases
(DAIDS/NIAID) grading system, 2004 revision [10]. An
ALT level of 1.25-2.5 times the upper limit of normal
(ULN) defined grade 1 hepatoxicity, 2.6-5 times the ULN
defined grade 2, 5.1-10 times the ULN defined grade 3,
and > 10 times the ULN defined grade 4 hepatoxicity.
Laboratory procedures
For HBV, women were tested using the Murex HBsAg
Version 3 with Confirmatory Assay (Murex Biotech,
Dartford, UK). The presence of HBeAg was assessed using
the ARCHITECT HBeAg Reagent Kit (Abbott Diagnostics
Division, Wiesbaden, Germany). Serum HBV-DNA
was quantified using the COBAS TaqMan HBV Test
(Roche Molecular System, Branchburg, NJ, USA) with
a limit of quantification of 6 IU/ml. For HCV all sera
were first tested with the Innotest HCV Ab IV assay
(Innogenetics, Ghent, Belgium). Low and high-positive
results were re-assayed using the Ortho HCV 3.0 ELISA
test (Ortho-Clinical Diagnostics, Raritan, NJ, USA). Sam-
ples reactive with both assays were considered anti-HCV
positive [11]. In anti-HCV positive women the presence of
HCV-RNA was tested in at least 3 different samples using
the Versant HCV-RNA 1.0 assay (Siemens Diagnostics)
with a detection limit of 15 IU/ml. Only patients with
detectable HCV-RNA were considered HCV-positive.
Data analysis
Characteristics in the hepatitis coinfected and the HIV
monoinfected groups were compared using the Mann–
Whitney test for continuous variables and the chi square
or Fisher’ s exact test for categorical variables. The
Kaplan-Meier method was used to define the time to the
development of liver toxicity and the Cox proportional
Andreotti et al. BMC Infectious Diseases 2014, 14:180 Page 2 of 8
http://www.biomedcentral.com/1471-2334/14/180
hazards model to identify factors associated with its emer-
gence. Variables were included in the multivariate model
if they were significant at a P value of less than 0.25 in
univariate analysis. For all statistical tests, two-sided P values
less than 0.05 were considered to be significant. Data
analysis was done using the SPSS software system 20.0
(IBM, Somers, NY, USA).
Results
A total of 309 HIV-infected women out of the total 311
enrolled in the study were tested for HBV and HCV
at baseline (before drug administration). Twenty-seven
women (8.7%) were HBsAg + and 1 (0.3%) was HCV-RNA
positive (8 women were positive only for anti-HCV
antibodies). Therefore, a total of 28 women out of
309 (9.1%) were coinfected with either HBV or HCV
virus. Among the 27 HBV-infected women, 10 (37%)
were HBeAg + and 18 out of the 24 tested (75%) had
detectable (> 6 IU/ml) HBV-DNA at baseline. Median
HBV-DNA among those with detectable DNA was
1,231 IU/ml (IQR 37–38,500,000). Eight out of 24 (33.3%)
had > 10,000 IU/ml, and all of them were HBeAg-positive.
Six of the 16 (37.5%) HBeAg-negative women tested
for HBV-DNA had un undetectable HBV viral load
(< 6 IU/ml), and the others had levels ≤ 2,000 IU/ml.
Eight women were lost to follow-up before delivery, 3
had a miscarriage and left the study and 48 (15.5%) were
lost between delivery and Month 24. A total of 147 women
(including 13 with coinfection) interrupted treatment
6 months postpartum when the risk of breastfeeding trans-
mission was ceased, while the remaining 162 (including
15 with coinfection), who had baseline CD4+ < 350/mm3,
continued antiretrovirals indefinitely. Women were followed
for a median of 111 weeks (IQR: 105–116). Patient charac-
teristics are reported in Table 1. At baseline only 2 mono-
infected women had a grade 1 ALT elevation; coinfected
women had a higher (although not clinically relevant)
ALT level compared to the HIV + only group (P = 0.043).
No other significant difference was observed at baseline
between the two groups.
Table 1 Patient characteristics
HBV or HCV coinfected (n.28) HIV + only (n. 281) P value
Age
Median (IQR) 27.5 (23–30) 27 (23–31) 0.960
WHO Stage N. (%)
I 17 (63) 211 (75.9) 0.493
II 7 (25.9) 47 (16.9)
III 3 (11.1) 19 (6.8)
IV 1 (0.4)
Week of gestation at ART initiation
Median (IQR) 27 (24–31) 26 (24–30) 0.576
Duration of ART during pregnancy
Median days (IQR) 78 (49–92) 70 (44–95) 0.828
ART regimen, N. (%)
Stavudine/Lamivudine/Nevirapine 15 (53.6) 148 (52.7)
Zidovudine/Lamivudine/Nevirapine 13 (46.4) 133 (47.3) 0.927
Baseline Hemoglobin (g/dl)
Median (IQR) 9.8 (9.0-10.9) 10.3 (9.5-11.3) 0.082
Baseline Platelets (x103/mm3)
Median (IQR) 177 (126–262) 202 (168–249) 0.106
Baseline ALT (IU/ml)
Median (IQR) 15.5 (12.2-27.1) 12.5 (10–17.8) 0.043
Baseline AST (IU/ml)
Median (IQR) 28 (23.3-37.1) 25.1 (19.3-34.2) 0.209
Baseline CD4+ cell count/mm3
Median (IQR) 327 (193–495) 340 (219–494) 0.666
Baseline HIV-RNA log10/ml
Median (IQR) 3.89 (3.0-4.5) 4.09 (3.4-4.6) 0.297
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Hepatoxicity
Over the total follow-up time 125 women (40.5%) devel-
oped a new grade ≥ 1 ALT elevation (15/28 or 53.6%
coinfected women and 110/281 or 39.1% HIV + only), 28
(9.1%) (2 coinfected and 26 HIV + only) a grade ≥ 2, and
6 (1.9%) (all HIV + only) a grade 3 toxicity. Twelve % of
the cases occurred during pregnancy and 57.6% within 6
months of delivery (83.3% of the cases in coinfected
women and 53.2% of the cases occurring in monoin-
fected women). In a Kaplan-Meier univariate analysis,
the risk of developing an ALT elevation of any grade was
higher for HBV or HCV infected women (P = 0.033 by
log-rank test), while no significant association was found
for grade ≥ 2 liver toxicity (P = 0.706) (Figure 1). In a
multivariate Cox model that adjusted for age, CD4+
count > or < 250/mm3 and hemoglobin level, the presence
of hepatitis B or C remained significantly associated with
the development of liver toxicity of any grade (hazard ratio
[HR]: 1.797, 95% CI 1.042-3.098, P = 0.035) (Table 2).
In a similar multivariate model, based on the same variables
reported above, but that considered only grade ≥ 2 ALT
elevations, the only predictor of the emergence of toxicity
was a baseline CD4+ cell count > 250/mm3 (HR: 3.296, 95%
CI 1.125-9.655, P = 0.030).
Fifteen cases of ALT increase of any grade and 8 cases of




























































Figure 1 Proportion of patients who experienced episodes of hepatoxicity of any grade (Panel A) or hepatoxicity of grade ≥ 2
(Panel B) by infection group.
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out of the 28 (46.4%) total cases of grade ≥ 2 toxicity
developed within the first 18 weeks of treatment. Of
these cases, 12 occurred in the 211 women with base-
line CD4+ > 250/mm3 and 1 among the 98 women with
baseline (CD4+ ≤ 250/mm3, P = 0.069). There was no
difference in the occurrence of toxicity after 18 weeks
according to the baseline CD4+ stratum.
In HBV-infected women, after controlling for age,
CD4+ count above or below 250/mm3 and hemoglobin
level, a baseline HBV-DNA level > 10,000 IU/ml was sig-
nificantly associated with the development of liver toxicity
of any grade (HR:3.278, 95% CI 1.056-10.180, P = 0.040).
HBV-DNA measurements during treatment were available
for 20 women at Month 6 and for 14 women at Month 12
postpartum. At 6 months 9/20 had a detectable HBV-DNA
level (but only 3 had levels > 10,000 IU/ml) while at 12
months 8/14 had detectable HBV-DNA levels (5 had levels
above 10,000 IU/ml), but it has to be considered that 6 of
these women, not meeting the criteria for treatment, had
interrupted treatment 6 months postpartum. Women with
detectable HBV-DNA at 6 months had a higher median
ALT level at 12 and 24 months compared to those with
undetectable HBV-DNA (59.2 vs 18.5 IU/ml and 35.9 vs
18.2 IU/ml, respectively, P = 0.001 and P = 0.043).
There was no difference in the probability of develop-
ing liver toxicity of any grade between women receiving
zidovudine or stavudine.
Among the 3 women who discontinued nevirapine be-
cause of liver toxicity none was coinfected.
Among the 6 women who died during follow-up, one was
coinfected with HBV (no death was liver-related). There
was no difference in the probability of survival between the
2 groups (P = 0.511 by log-rank test) (Figure 2).
Viro-immunological response
Among the 237 women with HIV-RNA determination
6 months postpartum, 21/23 coinfected women vs 160/214
HIV + only had < 50 HIV-RNA copies/ml (P = 0.118).
No difference was detected also considering the proportion
of women with HIV-RNA < 1,000 copies/ml (21/23 vs
197/214, P = 1.0). Among the women continuing therapy,
the proportion of women with < 50 copies/ml or < 1,000
copies/ml was not significantly different between the
coinfected and the monoinfected populations at Month
12 or 24 (Figure 3).
Median CD4+ increase at Month 6 was 185 cells/mm3,
with no difference between the two groups (185 cells
in the monoinfected vs 179 cells in the coinfected group,
P = 0.819) (Figure 4). Among the women continuing ther-
apy, the median CD4+ increases at Month 12 and Month
24 were 218 and 294 cells, respectively with no differ-
ence between those coinfected and those HIV + only
(279 vs 217 cells, and 439 vs 294 cells, respectively, P = 0.123
and P = 0.172).
Discussion
Emergence of severe liver toxicity in this cohort of women
was infrequent. Women with either coinfection had a
Table 2 Cox proportional hazards analysis of factors associated with the emergence of hepatotoxicity of any grade
Variable Univariate analysis Multivariable analysis
Hazard ratio (95% CI) P value Hazard ratio ( 95% CI) P value
Age (per 1-year increase) 1.021 (0.987-1.057) 0.230 1.025 (0.990-1.061) 0.162
CD4+ cell count (>250/mm3 vs ≤ 250/mm3) 1.257 (0.853-1.851) 0.247 1.397 (0.940-2.075) 0.098
Hemoglobin (<median level of 10.3 g/dl vs≥median) 1.275 (0.897-1.811) 0.176 1.320 (0.924-1.886) 0.128



















Figure 2 Proportion of deaths by infection group.
Andreotti et al. BMC Infectious Diseases 2014, 14:180 Page 5 of 8
http://www.biomedcentral.com/1471-2334/14/180
higher risk of mild hepatoxicity, mainly occurring in the
first 6 months of treatment, and among the HBV-positive
women baseline levels of HBV-DNA above 10,000 IU/ml
were significantly associated with the emergence of tox-
icity. However, it has to be underlined that a significant
association was found only for grade ≥ 1 ALT increases,
while no effect was found for the occurrence of moder-
ate to severe liver toxicity, suggesting an overall impact
of modest magnitude.
More frequent ALT elevations were observed in coin-
fected patients in other reports [2-4,6,7] and HBV-DNA
was found to be associated with liver toxicity in some
studies [5] but not in others [6]. Our finding of a correlation
between detectable levels of HBV-DNA during follow-up
and values of ALT supports the role of actively replicat-
ing HBV infection in the occurrence of liver toxicity.
In our study both incomplete response to therapy and
interruption of treatment 6 months postpartum for women
not meeting the criteria for treatment, could be respon-
sible for high HBV-DNA levels during follow-up. At
this regard, recent World Health Organization guidelines
for the prevention of vertical transmission of HIV [12],
recommending life-long antiretroviral therapy containing
two anti-HBV active agents for all pregnant women, repre-
sent an important step to minimize the risk of hepatic
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HIV+ only N. 279 226 206 183 211
Coinfected N. 28 22 21 15 21
Figure 4 CD4+ cell counts during follow-up by infection group.
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High levels of CD4+ are known to be associated with
nevirapine-induced liver toxicity [13], and in our co-
hort of nevirapine-treated women baseline levels of
CD4+ > 250/mm3 were indeed correlated to the emer-
gence of grade ≥ 2 ALT elevation. Liver toxicity associated
with nevirapine is supposed to occur more frequently in
the first 18 weeks of treatment, and in our study grade ≥ 2
early toxicity occurred almost exclusively among women
with baseline CD4+ count > 250/mm3. However, the
overall incidence of moderate or severe liver toxicity (9%)
was relatively low, considering the long-term follow-up
(and less than 1% of the women discontinued nevirapine
because of liver toxicity), thus confirming our previous ob-
servation of a relative safety of using nevirapine in this
context [14]. Also, only 2.5% of the women in our study
had grade ≥ 2 events during pregnancy in line with the
findings of a recent meta-analysis [15], indicating that
drug adverse events were not greater in pregnant
women receiving nevirapine than in the general population.
The findings of a study performed in Cameroon [7], in
patients with CD4+ < 350/mm3, have also suggested that
a nevirapine-based antiretroviral regimen could be used
safely as first-line therapy despite frequent coinfections
with the hepatitis viruses.
Previous studies have evaluated the impact of HBV or
HCV on the response to ART in resource-limited settings.
Although a limited impact of coinfections has been shown
on the antiretroviral response, some studies [4,16] have
shown a negative effect on the CD4+ response in HBV-
coinfected patients, especially in those with HBe or high
HBV-DNA levels, and some a slower virological response
[6]. The low numbers in our study limited the power to
detect significant differences in the viro-immunological
parameters however, we did not observe any negative
trend in terms of long-term virological suppression
and immunological response.
Our study also confirmed that in Malawi HBV infection
is highly prevalent in the HIV-positive population [17]
with more than 8% of the HIV-infected women positive
for HBsAg in our cohort, and that HCV is quite rare, in
line with other findings [18]. Among the HBV-infected
women, HBe antigen was present in about one third of
patients, in agreement with previous reports [16], while
the proportion of those with > 10,000 IU/ml of HBV-DNA
was low compared to other studies [3,16]. A role of differ-
ent genotypes can be hypothesized since genotypes C, D
and F are associated to higher DNA levels compared to
other genotypes [3] and in Malawi genotype A is highly
dominant [19].
Limitations of this study include: the small number of
coinfected women in the cohort that often did not allow
to draw statistically significant conclusions; the lack of
treatment adherence measures to determine the possible
impact of unscheduled suspension of drugs; and incomplete
data on the HBV-DNA levels during follow-up in the
HBV-infected women, although the available data support
the role of actively replicating infection in determining
liver enzymes elevations.
Conclusions
In this cohort of HIV-infected nevirapine-treated pregnant
women in Malawi the presence of HBV or HCV infection
seemed not to have a major impact on the emergence
of moderate to severe liver toxicity and on the response to
antiretroviral treatment up to 24 months after delivery.
High baseline levels of HBV-DNA were significantly asso-
ciated with the emergence of mild liver toxicity. Screening
for the hepatitis viruses in these settings could be useful
to identify the women that could benefit from a closer
monitoring strategy.
Abbreviation
HBV: Hepatitis B virus; HCV: Hepatitis C virus; HBsAg: Hepatitis B surface antigen.
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